Here’s how analysts see Verastem, Inc. (NASDAQ:VSTM) after this past week.

October 13, 2018 - By Hazel Jackson

Investors sentiment increased to 2.07 in Q2 2018. Its up 0.91, from 1.16 in 2018Q1. It increased, as 15 investors sold Verastem, Inc. shares while 15 reduced holdings. 36 funds opened positions while 26 raised stakes. 30.86 million shares or 129.37% more from 13.46 million shares in 2018Q1 were reported.
Howland Limited Co accumulated 267,593 shares. Barclays Public Limited Company invested in 3,879 shares. Moreover, Tci Wealth Advisors has 0% invested in Verastem, Inc. (NASDAQ:VSTM). Barrett Asset Mgmt Limited Liability Corp reported 50,000 shares. Morgan Stanley reported 175,658 shares stake. Blackrock holds 3.54M shares. 542,977 are held by Dimensional Fund Advsrs L P. Creative Planning holds 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 58,550 shares. Voya Inv Ltd Liability holds 0% or 20,274 shares. Jpmorgan Chase Company owns 174,573 shares or 0% of their US portfolio. Hartford Fin Mngmt Inc holds 0% or 2,000 shares in its portfolio. Bank Of Montreal Can invested 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Advisory Services Ntwk Ltd Liability Com invested in 0.01% or 22,025 shares. First Allied Advisory Ser has invested 0.01% in Verastem, Inc. (NASDAQ:VSTM). Vanguard Gp has 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 2.60M shares.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Among 3 analysts covering Verastem (NASDAQ:VSTM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Verastem had 4 analyst reports since May 2, 2018 according to SRatingsIntel. On Thursday, May 10 the stock rating was maintained by FBR Capital with “Buy”. As per Friday, June 8, the company rating was maintained by FBR Capital. Below is a list of Verastem, Inc. (NASDAQ:VSTM) latest ratings and price target changes.

13/07/2018 Broker: BTIG Research Rating: Buy New Target: $17 Initiates Coverage On
08/06/2018 Broker: FBR Capital Rating: Buy New Target: $17.0000 Maintain
10/05/2018 Broker: FBR Capital Rating: Buy New Target: $17.0000 Maintain
02/05/2018 Broker: Seaport Global Rating: Buy New Target: $14 Initiates Coverage On

The stock decreased 9.31% or $0.58 during the last trading session, reaching $5.65. About 9.88 million shares traded or 233.94% up from the average. Verastem, Inc. (NASDAQ:VSTM) has risen 69.08% since October 13, 2017 and is uptrending. It has outperformed by 53.46% the S&P500.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $415.80 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

More notable recent Verastem, Inc. (NASDAQ:VSTM) news were published by: Businesswire.com which released: “Verastem Oncology Announces Pricing of Registered Direct Offering of $150 Million of Convertible Notes” on October 11, 2018, also Benzinga.com with their article: “41 Stocks Moving In Friday’s Mid-Day Session” published on October 12, 2018, Seekingalpha.com published: “Verastem: Post FDA Approval Investment Thesis” on September 27, 2018. More interesting news about Verastem, Inc. (NASDAQ:VSTM) were released by: Seekingalpha.com and their article: “Verastem Oncology prices registered direct offering of $150M convertible notes” published on October 12, 2018 as well as Fool.com‘s news article titled: “Here’s Why Verastem Dropped Precipitously Today” with publication date: October 12, 2018.

Verastem, Inc. (NASDAQ:VSTM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>